Deals
AstraZeneca Eyes Gilead in Big Pharma’s Move Beyond Covid
- U.K. drugmaker said to make preliminary approach to U.S. rival
- Industry’s big players face new pressure to grow and innovate
This article is for subscribers only.
Two drugmakers behind the industry’s most prominent responses to the Covid-19 pandemic are looking into the possibility of a combined future as economies emerge from lockdowns.
AstraZeneca Plc, co-developer of one of the fastest-moving experimental coronavirus vaccines, has made a preliminary approach to Gilead Sciences Inc., maker of the only U.S.-approved treatment, according to people familiar with the matter. If they decided to pursue a merger, it would rank as the biggest deal ever in the sector.